VORICONAZOLE GENPAR voriconazole 200 mg powder for injection vial

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

voriconazole, Quantity: 200 mg

Available from:

MedTAS Pty Ltd

INN (International Name):

Voriconazole

Pharmaceutical form:

Injection, powder for

Composition:

Excipient Ingredients: hydroxypropylbetadex; sodium chloride

Administration route:

Intracranial, Intravenous

Units in package:

1

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

Voriconazole is indicated for treatment of the following fungal infections: Invasive aspergillosis. Serious Candida infections (including C. krusei), including oesophageal and systemic Candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). Serious fungal infections caused by Scedosporium spp and Fusarium spp.Other serious fungal infections, in patients intolerant of, or refractory to, other therapy. Prophylaxis in patients who are at high risk of developing invasive fungal infections. The indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

Product summary:

Visual Identification: White to off white lyophilized powder; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius

Authorization status:

Licence status A

Authorization date:

2016-07-22